Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
暂无分享,去创建一个
D. Neuberg | M. Mihm | A. Berns | F. Hodi | G. Dranoff | A. Sober | R. Mulligan | R. Soiffer | A. Berns | A. Cosimi | J. Daley | J. Drayer | K. Tanabe | A. Bhan | S. Mentzer | R Soiffer | T Lynch | M Mihm | K Jung | C Rhuda | J C Schmollinger | F S Hodi | L Liebster | P Lam | S Mentzer | S Singer | K K Tanabe | A B Cosimi | R Duda | A Sober | A Bhan | J Daley | D Neuberg | G Parry | J Rokovich | L Richards | J Drayer | A Berns | S Clift | L K Cohen | R C Mulligan | G Dranoff | J. Rokovich | L. Cohen | K. Tanabe | S. Clift | C. Rhuda | J. Schmollinger | T. Lynch | K. Jung | L. Liebster | P. Lam | R. Duda | S. Singer | A. Sober | A. Bhan | G. Parry | L. Richards | S. Clift | Cosimi Ab | Gareth Parry
[1] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[2] R. Elashoff,et al. Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine , 1992, Annals of surgery.
[3] D. Roses,et al. Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. , 1989, Journal of biological response modifiers.
[4] W. Clark,et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.
[5] J. W. Osborne,et al. Dermal hypersensitivity to schistosome cercariae in rhesus monkeys during immunization and challenge: I. Complex hypersensitivity reactions of a well-immunized monkey during the challenge , 1974 .
[6] M. Mihm,et al. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[7] F. Oesch,et al. Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.
[8] J. Ozols,et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[9] P. Banks,et al. Long‐term spontaneous regression of malignant melanoma with visceral metastases Report of a case with immunologic profile , 1975, Cancer.
[10] R. Coffman,et al. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. , 1989, Science.
[11] C. Farina,et al. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. , 1997, The Journal of clinical investigation.
[12] D. Morton,et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. , 1994, Cancer research.
[13] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[14] C. Slingluff,et al. Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients , 1988, Journal of surgical oncology.
[15] G. Carcelain,et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. , 1994, The Journal of clinical investigation.
[16] M. Mihm,et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. , 1997, Human gene therapy.
[17] T. Yokota,et al. Cytokines: coordinators of immune and inflammatory responses. , 1990, Annual review of biochemistry.
[18] F. Marshall,et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.
[19] A. Mackensen,et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. , 1993, The Journal of clinical investigation.
[20] G. Dranoff,et al. Gene transfer as cancer therapy. , 1995, Advances in immunology.
[21] M. Mitchell,et al. Active specific immunotherapy of melanoma. , 1990, British medical bulletin.
[22] G. Gleich,et al. The eosinophilic leukocyte: structure and function. , 1986, Advances in immunology.
[23] G. Murphy,et al. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. , 1991, Cancer research.
[24] N. Cascinelli,et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.
[25] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[26] G. Wong,et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Hauck,et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.